CML Highlights of EHA 2025 - Clinical Overview incl. Q&A Session
Автор: International CML Foundation
Загружено: 2025-08-11
Просмотров: 890
This is the second of two parts of the iCMLf Conversation on CML held on the 22nd of July 2025. To view the first part, CML Highlights of EHA - Biological Overview, go here: • CML Highlights of EHA 2025 - Biological Ov...
Expert:
Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital (Germany)
Program:
Overview of significant clinical aspects presented during the meeting, including:
01:15 2025 European LeukemiaNet (ELN) recommendations for the management of CML (Jane Apperley on behalf of the ELN Consensus Panel)
10:49 Asciminib shows superior tolerability versus nilotinib in newly diagnosed CML in chronic-phase: Primary results of the Phase 3b ASC4START Trial (Andreas Hochhaus)
13:04 CML treatment discontinuation after a two-step dose reduction. First results of the phase 2 study HALF (Jiří Mayer)
15:19 ENABLE: A phase 1a/1b study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML (Andreas Hochhaus)
18:00 Characterization and efficacy of TERN-701 in pre-clinical models of CML (Timothy Hughes)
20:42 Q&A Session (covering biological and clinical questions)
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
